Entera Bio (ENTX) Expected to Announce Quarterly Earnings on Friday

Entera Bio (NASDAQ:ENTX) is projected to release its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect Entera Bio to post earnings of ($0.09) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 14, 2025 at 7:00 AM ET.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.05. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 77.75%. On average, analysts expect Entera Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Entera Bio Stock Up 2.3%

Shares of Entera Bio stock opened at $3.11 on Friday. Entera Bio has a twelve month low of $1.50 and a twelve month high of $3.22. The business has a 50-day moving average price of $2.18 and a 200-day moving average price of $2.06. The firm has a market cap of $142.00 million, a price-to-earnings ratio of -11.96 and a beta of 1.67.

Wall Street Analysts Forecast Growth

ENTX has been the topic of a number of research reports. HC Wainwright raised Entera Bio to a “strong-buy” rating in a research note on Monday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.